Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

2-14-2020

Treatment de-escalation for HPV-associated oropharyngeal
squamous cell carcinoma with radiotherapy vs. trans-oral surgery
(ORATOR2): study protocol for a randomized phase II trial.
Anthony C Nichols
Pencilla Lang
Eitan Prisman
Eric Berthelet
Eric Tran

See next page for additional authors
Follow this and additional works at: https://ir.lib.uwo.ca/paedpub
Part of the Pediatrics Commons

Citation of this paper:
Nichols, Anthony C; Lang, Pencilla; Prisman, Eitan; Berthelet, Eric; Tran, Eric; Hamilton, Sarah; Wu, Jonn;
Fung, Kevin; de Almeida, John R; Bayley, Andrew; Goldstein, David P; Eskander, Antoine; Husain, Zain;
Bahig, Houda; Christopoulous, Apostolos; Hier, Michael; Sultanem, Khalil; Richardson, Keith; Mlynarek,
Alex; Krishnan, Suren; Le, Hien; Yoo, John; MacNeil, S Danielle; Mendez, Adrian; Winquist, Eric; Read,
Nancy; Venkatesan, Varagur; Kuruvilla, Sara; Warner, Andrew; Mitchell, Sylvia; Corsten, Martin; Rajaraman,
Murali; Johnson-Obaseki, Stephanie; Eapen, Libni; Odell, Michael; Chandarana, Shamir; Banerjee, Robyn;
Dort, Joseph; Matthews, T Wayne; Hart, Robert; Kerr, Paul; Dowthwaite, Samuel; Gupta, Michael; Zhang,
Han; Wright, Jim; Parker, Christina; Wehrli, Bret; Kwan, Keith; Theurer, Julie; and Palma, David A,
"Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy
vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial." (2020). Paediatrics
Publications. 468.
https://ir.lib.uwo.ca/paedpub/468

Authors
Anthony C Nichols, Pencilla Lang, Eitan Prisman, Eric Berthelet, Eric Tran, Sarah Hamilton, Jonn Wu, Kevin
Fung, John R de Almeida, Andrew Bayley, David P Goldstein, Antoine Eskander, Zain Husain, Houda Bahig,
Apostolos Christopoulous, Michael Hier, Khalil Sultanem, Keith Richardson, Alex Mlynarek, Suren
Krishnan, Hien Le, John Yoo, S Danielle MacNeil, Adrian Mendez, Eric Winquist, Nancy Read, Varagur
Venkatesan, Sara Kuruvilla, Andrew Warner, Sylvia Mitchell, Martin Corsten, Murali Rajaraman, Stephanie
Johnson-Obaseki, Libni Eapen, Michael Odell, Shamir Chandarana, Robyn Banerjee, Joseph Dort, T Wayne
Matthews, Robert Hart, Paul Kerr, Samuel Dowthwaite, Michael Gupta, Han Zhang, Jim Wright, Christina
Parker, Bret Wehrli, Keith Kwan, Julie Theurer, and David A Palma

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/468

Nichols et al. BMC Cancer
(2020) 20:125
https://doi.org/10.1186/s12885-020-6607-z

STUDY PROTOCOL

Open Access

Treatment de-escalation for HPV-associated
oropharyngeal squamous cell carcinoma
with radiotherapy vs. trans-oral surgery
(ORATOR2): study protocol for a
randomized phase II trial
Anthony C. Nichols1, Pencilla Lang2, Eitan Prisman3, Eric Berthelet4, Eric Tran4, Sarah Hamilton4, Jonn Wu4,
Kevin Fung1, John R. de Almeida5, Andrew Bayley6, David P. Goldstein5, Antoine Eskander7, Zain Husain8,
Houda Bahig9, Apostolos Christopoulous10, Michael Hier11, Khalil Sultanem12, Keith Richardson11, Alex Mlynarek11,
Suren Krishnan13, Hien Le14, John Yoo1, S. Danielle MacNeil1, Adrian Mendez1, Eric Winquist15, Nancy Read2,
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Han Zhang23, Jim Wright24, Christina Parker25, Bret Wehrli26, Keith Kwan26, Julie Theurer27 and David A. Palma2*

Abstract
Background: Patients with human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPC)
have substantially better treatment response and overall survival (OS) than patients with HPV-negative disease.
Treatment options for HPV+ OPC can involve either a primary radiotherapy (RT) approach (± concomitant
chemotherapy) or a primary surgical approach (± adjuvant radiation) with transoral surgery (TOS). These two
treatment paradigms have different spectrums of toxicity. The goals of this study are to assess the OS of two deescalation approaches (primary radiotherapy and primary TOS) compared to historical control, and to compare
survival, toxicity and quality of life (QOL) profiles between the two approaches.
Methods: This is a multicenter phase II study randomizing one hundred and forty patients with T1–2 N0–2 HPV+
OPC in a 1:1 ratio between de-escalated primary radiotherapy (60 Gy) ± concomitant chemotherapy and TOS ± deescalated adjuvant radiotherapy (50–60 Gy based on risk factors). Patients will be stratified based on smoking status
(< 10 vs. ≥ 10 pack-years). The primary endpoint is OS of each arm compared to historical control; we hypothesize
that a 2-year OS of 85% or greater will be achieved. Secondary endpoints include progression free survival, QOL
and toxicity.
Discussion: This study will provide an assessment of two de-escalation approaches to the treatment of HPV+ OPC
on oncologic outcomes, QOL and toxicity. Results will inform the design of future definitive phase III trials.
(Continued on next page)
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Background
Oropharyngeal squamous cell carcinoma (OPC) is rapidly increasing in incidence, associated with rising rates
of human papillomavirus (HPV) infection [1, 2]. Patients
with HPV-positive (HPV+) OPC have substantially better treatment response and overall survival (OS) than patients with HPV-negative (HPV-) disease [3]. Historically
the management of OPC has relied on radiotherapy
(RT) based approaches as older surgical techniques required large incisions and mandibulotomies with high
surgical morbidity and mortality [4]. The addition of
concurrent chemotherapy to radiation improved oncological outcomes [5]. However, acute and long term side
effects of RT or chemoradiation (CRT) can be severe, including frequent swallowing dysfunction, mucositis, xerostomia, fibrosis, osteoradionecrosis, neutropenia,
neurotoxicity and hearing loss [6].
The introduction of minimally invasive transoral surgical techniques including transoral robotic surgery (TORS)
and transoral laser microsurgery (TLM) has led to a revival of surgery as the primary treatment of OPC [7, 8].
While primary surgery with transoral surgery (TOS) can
avoid some of the side effects of radiotherapy, it can have
rare serious consequences such as fatal hemorrhage,
stroke, shoulder dysfunction and dysphagia [9].
Currently, there is no level I evidence to favor one treatment strategy over the other. Instead, treatment selection
is largely driven by institutional and patient biases with
the majority of patients in the United States receiving surgery (82% of T1-T2 disease) [7], while most patients receive primary RT in Canada and Europe [10, 11].
The ORATOR trial is the only trial to examine the
question of a primary RT vs. primary TOS approach in a
randomized fashion [12]. This phase II trial included 68
patients with OPC regardless of HPV status, and randomized patients to RT (70 Gy, with chemotherapy if
N1–2) or TOS plus neck dissection (with or without adjuvant RT/CRT, based on pathology). The primary endpoint was swallowing-related quality of life (QOL) at 1
year, measured using the MD Anderson Dysphagia Inventory (MDADI) [13]. The study found that at 1 year
there was a statistically significant difference in swallowing QOL but that this difference did not represent a
clinically meaningful change (less than a 10-point
difference).

Since the ORATOR trial opened in 2012, the landscape has further shifted to recognize the clinical importance of HPV status. The impact of HPV on
outcomes has been so substantial that a separate staging
system has been created to better represent the prognosis of these patients [3, 14]. Although not yet part of
routine clinical care, research is now focused on deintensification of treatment in HPV+ OPC, in an attempt
to reduce adverse events while maintaining excellent oncologic outcomes. Patients with HPV-related OPC have
an excellent chance of survival, and therefore may have
to deal with the sequelae of therapy for many decades
[3]. With excellent rates of cure, post-treatment QOL
becomes of paramount importance. Trials focusing on
both primary RT and primary surgical approaches have
de-escalated radiotherapy doses; two key trials that are
currently underway include NRG-HN-002 and ECOG3311 [15, 16].
NRG-HN-002 [15] included 308 patients in a phase II
parallel-arm design investigating de-intensification in a
low-risk p16+ population (T1–2 N1-N2b or T3 N0-N2b
as per AJCC 7th edition, and ≤ 10 pack-year smoking history). Arm 1 was conventionally fractionated CRT with
60 Gy (2 Gy/fraction) given in 6 weeks with weekly cisplatin 40 mg/m2 and Arm 2 was accelerated RT alone with
60 Gy (2 Gy/fraction) given in 5 weeks with 6 fractions per
week. The trial had co-primary endpoints with
progression-free survival (PFS) and QOL at 2 years with
acceptability criterion of PFS of ≥85% and an MDADI
score ≥ 60. Early results presented in abstract format
showed the CRT arm met the acceptability criteria for
both PFS and MDADI, while the accelerated radiotherapy
arm did not meet the PFS acceptability criterion [15].
ECOG-3311 focuses on a primary surgical approach
for cT1–2 N1–2b (as per AJCC 7th edition) HPV+ OPC
patients, de-escalating the adjuvant RT dose for intermediate risk patients based on surgical pathology. After
resection, if a patient has any of: close margins, < 1 mm
of extranodal extension (ENE), 2–4 lymph nodes (LN)
involved, perineural invasion (PNI) or lymphovascular
invasion (LVI) they are randomized in a 1:1 ratio to
standard dose adjuvant RT (60 Gy) or de-escalated adjuvant RT (50 Gy). The primary endpoint for this trial is
PFS. This trial has completed accrual, but results are not
yet reported [16].
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Given the dramatic rise in the incidence of HPV disease and the paucity of high-quality data comparing
treatment options, the management of HPV+ OPC is arguably the most contentious issue in head and neck oncology [17, 18]. The purpose of this randomized trial is
to assess the safety of two de-escalation approaches (primary RT and primary surgery) in early T stage HPV+
OPC by comparing to historical control, and to compare
survival, toxicity and QOL profiles between the two approaches. The primary radiotherapy approach is based
on the chemoradiation arm of HN002, and the primary
surgery approach is based on the treatment paradigm of
ECOG-3311 [15, 16].

Methods/design
The objectives of this trial are to:
1. Compare OS relative to historical controls for deintensified primary radiotherapy [60 Gy ± chemotherapy] versus TOS and neck dissection [± adjuvant 50 Gy radiotherapy] in patients with early Tstage HPV+ squamous cell carcinoma of the
oropharynx.
2. Compare PFS, toxicity and QOL profiles.
Our hypothesis is that for patients with HPV+ T1–
2N0–2 (as per AJCC 8th edition) OPC, de-intensified
primary RT and primary surgery with de-intensified adjuvant therapy will achieve 2-year OS rates of 85% or
greater.
Study design

This study is an open-label phase II multi-centre randomized trial, and is designed to assess two potential

Fig. 1 Study Schema
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treatment de-escalation approaches, comparing each to
a historical control, with the potential goal of evaluating
one or both compared to standard CRT in a subsequent
phase III trial. The required sample size is 140 patients.
Participating centres will be tertiary, academic hospitals
or radiotherapy treatment centres in Canada (updated
list of participating centres available on clinicaltrials.gov:
identifier NCT03210103). Patients will be randomized
between a primary RT-based approach (Arm 1) vs. a primary surgical approach (Arm 2) in a 1:1 ratio using a
permutated block design (Fig. 1). There will be one
stratification factor: smoking status (< 10 vs. ≥ 10 packyears). Arm 1 of this trial is based on the chemoradiation arm of HN002 (60 Gy ± concomitant weekly cisplatin based on clinical nodal disease) [15], and Arm 2 is
similar to the treatment paradigm of ECOG-3311
(TOS ± adjuvant RT (50–60 Gy) based on risk factors)
[16].
Primary endpoint
 OS

Defined as time from randomization to death
from any cause
This study was originally launched with a primary endpoint of PFS. The results of the original ORATOR trial
became available in February 2019. These suggested that
OS would be a preferred endpoint for ORATOR2 as
both arms in ORATOR showed excellent OS in p16+
cancers (both > 92% at 2 years). OS is preferred as the
primary endpoint to evaluate de-escalation, since it was
evident in ORATOR that progression events, whether
local, regional, or distant, can often be salvaged for cure
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with surgery, radiation, or systemic therapy including
immunotherapy. Therefore, in Feb 2019, without knowledge of outcomes data from ORATOR2, this trial was
amended to promote OS from a secondary to primary
endpoint, and demote PFS to a secondary endpoint.
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Secondary endpoints
 2-year PFS (comparison with historical controls)









Time from randomization to disease
progression at any site or death PFS events are
defined as death from any cause, or first
recurrence of tumor at any site (including local,
regional, or distant). Second primary tumors (e.g.
head and neck cancer at a different site, such as
laryngeal cancer) will not be included as PFS
events.
2-year OS and PFS comparisons between Arm 1 and
Arm 2
Swallowing-related QOL at 1-year post-treatment
Assessed using the MDADI
QOL at other time points
Assessed using the MDADI, the European
Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Cancer Patients
general (QLQ-C30) and head & neck (H&N35)
scales, the Voice Handicap Index (VHI-10), the
Neck Dissection Impairment Index (NDII), the
Patient Neurotoxicity Questionnaire (PNQ), and
the EuroQOL 5-Dimension 5-Level (EQ-5D-5 L).
Toxicity
Assessed by the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 4
Other functional measurements, including,
measured by:
Feeding tube rate at 1-year
Common Toxicity Criteria for Adverse Events
(CTC-AE) Dysphagia scores







Exclusion criteria
 Unambiguous clinical or radiological evidence of





Inclusion criteria
 Minimum age 18
 Willing to provide informed consent
 Eastern Cooperative Oncology Group (ECOG)







performance status 0–2
Histologically confirmed squamous cell carcinoma
HPV+ tumor, as determined by: positive p16 status,
real-time polymerase chain reaction (PCR) or in-situ
hybridization. Central confirmation is not required.
Primary tumor site in the oropharynx (includes
tonsil, base of tongue, soft palate, walls of
oropharynx)
Eligible for curative intent treatment, with likely
negative resection margins at surgery. For patients

where adequate transoral access is in question, they
will first have an examination under anesthesia
ensure adequate exposure can be obtained prior to
randomization.
Smokers and non-smokers are included. Patients will
be stratified by < 10 versus ≥10 pack-year smoking
history. Pack-years are calculated by multiplying the
number of years smoked by the number of packs of
cigarettes smoked per day. One pack is considered
to contain 20 cigarettes.
Tumor stage (AJCC 8th edition): T1 or T2
Nodal stage (AJCC 8th edition): N0, N1 or N2
For patients who may require chemotherapy (i.e.
patients with multiple lymph nodes positive or a
single node more than 3 cm in size, in any plane; see
section 6): complete blood count/differential
obtained within 4 weeks prior to randomization,
with adequate bone marrow function, hepatic, and
renal function, defined as: Absolute neutrophil count
> 1.5 × 109/L; Hemoglobin > 80 g/L; platelets > 100 ×
109/L; Bilirubin < 35 μmol/L; AST, ALT < 3 x the
upper limit of normal; serum creatinine < 130 μmol/
L or creatinine clearance ≥50 mL/min
Head and neck multidisciplinary clinic (radiation
oncologist and surgeon) and multidisciplinary tumor
board presentation prior to randomization.





ENE on pre-treatment imaging. This includes the
presence of matted nodes, defined as 3 or more
nodes that are abutting with loss of intervening fat
planes.
Serious medical comorbidities or other
contraindications to RT, surgery or chemotherapy
Inability to attend full course of RT or follow-up
visits
History of previous head and neck RT or previous
head and neck cancer within 5 years
Metastatic disease present
Prior invasive malignant disease within 5 years, with
the exception of non-melanoma skin cancer
Lactating or pregnant women

Pre-treatment evaluation

The following evaluations are required:
 History and physical examination (including

laryngopharyngoscopy) by a radiation oncologist and
head and neck surgeon within 8 weeks prior to
randomization
 For patients where adequate transoral access is in
question, they will have an examination under
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anesthesia to ensure adequate exposure can be
obtained prior to randomization
Staging imaging within 12 weeks prior to
randomization: Contrast-enhanced CT of the neck
and chest or MRI of the neck with CT of the chest
or whole body PET/CT
Documentation of smoking history
Histological confirmation of squamous cell
carcinoma
p16+ or HPV+ tumor status, as defined above
Dental evaluation within 6 weeks prior to
randomization
Audiogram before initiation of treatment, with
baseline CTCAE grade assessment
Assessment of all baseline symptoms, including
assessment of dysphagia, using CTC-AE version 4
within 2 weeks prior to randomization. Baseline dysphagia CTC-AE will be scored in all patients.
Completion of QOL scoring within 2 weeks of
randomization
CBC/differential, hepatic (AST, ALT, total bilirubin)
and renal function testing (BUN and creatinine, or
creatinine clearance) within 4 weeks prior to
randomization, if chemotherapy would be required
Pregnancy test for women of child-bearing age,
within 2 weeks prior to randomization
Blood sample for whole genome sequencing analysis
prior to initiation of treatment
Informed consents must be obtained prior to any
study specific activities

Interventions

Initiation of treatment should occur within 4 weeks of
randomization.
Primary radiotherapy (Arm 1)

Treatment in this arm is generally based on Arm 1 of
NRG-HN002 [15], and may consist of either radiotherapy
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alone or concurrent chemoradiation depending on the patient’s clinical nodal status (see Table 1).
Dose levels are as follows:
 60 Gy in 30 fractions: Gross Tumor and Involved

Nodes
 54 Gy in 30 fractions: High risk subclinical areas.
 48 Gy in 30 fractions: Low-risk nodal areas

Specific radiotherapy volume definitions for Arm 1 are
described in Table 2. In all cases a 5 mm CTV to PTV
expansion is to be used.
Treatment breaks, early RT termination and discontinuation of systemic therapy is at the discretion of
the treating oncologist based on patient treatment
toxicity.
Salvage surgery Treatment response will be evaluated
10–12 weeks after completion of RT. This can be done
using a CT scan and/or a PET-CT scan.
Treatment of residual disease at the site of the primary
tumor will be determined by the treating physicians, and
should include surgical salvage if feasible.
Management of residual enlarged lymph nodes in the
neck should be guided by standard institutional practice.
In general, for patients with residual enlarged nodes on
CT, a PET-CT is preferred to confirm fluorodeoxyglucose (FDG) avidity prior to neck dissection. If the PETCT is negative in the setting of enlarged nodes on CT,
then close interval follow-up with repeat CT every 2–3
months is recommended until the lymph nodes resolve.
If PET-CT is unavailable, any nodes > 1 cm in short axis
should, at a minimum, be carefully followed with repeat
CT every 2–3 months until the lymph nodes resolve,
with neck dissection at the discretion of the treating
physician.
Salvage surgery for the primary tumor or lymph nodes
within 5 months of treatment will be considered part of
the initial treatment package and scored as persistent

Table 1 Delivery of radiation ± chemotherapy depending on clinical nodal status in Arm 1 (Primary RT)
Radiation Alone: Accelerated radiation

Concurrent chemotherapy: Weekly cisplatin 40 mg/m2 for 6 cycles

Nodal status

Node negative (N0)
OR
Single node less than 3 cm
in maximal diameter

Multiple lymph nodes
OR
Single lymph node more
than 3 cm in maximal diameter

Fractionation

Radiation over 5 weeks, with
6 fractions a week
6th weekly fraction given on
a weekday with a minimum 6 h
intrafraction interval, or on a Saturday

Daily radiation, Monday-Friday
over 6 weeks

Special conditions

In patients > 70 years of age, standard
fractionation (daily, Monday-Friday over
6 weeks) can be used at the discretion
of the radiation oncologist

In patients who are deemed unfit
for weekly cisplatin, the dose and/or
schedule can be modified, or cetuximab
or weekly carboplatin AUC 1.5 can be used,
at the discretion of the medical oncologist.
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Table 2 Specific RT volume definition volumes for Arm 1
(Primary RT)
Radiotherapy Volume

Definition

GTV_P

Gross tumour volume

GTV_N

Gross nodes:
– > 1.5 cm long axis
– > 1 cm short axis
– Necrotic
– PET positive

CTV60

Combination of GTV_P
and GTV_N with a 5 mm
expansion, excluding
natural boundaries of
spread

CTV54

– A 1 cm expansion on
the GTV_P
– Any nodal level that
contains a
positive node.
– Any node < 1 cm in
short axis the
radiation oncologist deems
suspicious for harbouring
disease. This node plus
an additional 5 mm margin
will be
included in the CTV54.
– The first echelon draining
nodal levels. This is nearly
always level 2, but should
include the lateral retropharyngeal
nodes (RP) for soft palate and
posterior pharyngeal wall
extension.

CTV48

– Patients that are node negative:
Ipsilateral: II-IV. RP only if
extension to posterior pharyngeal
wall or soft palate
Contralaterala: II-IV, RP only if
extension to posterior pharyngeal
wall or soft palate
– All patients with N1 (ipsilateral)
nodal disease:
Ipsilateral: Ib, II-V, RP
Contralaterala: II-IV, RP only if
extension to
posterior pharyngeal wall or soft
palate
– All patients with N2 disease:
Ipsilateral and contralateral:
Ib, II-V, RP

a

If treating the contralateral neck

disease, not as recurrence. Surgery beyond 5 months posttreatment will be scored as recurrence if malignancy is
evident in the pathology specimen.
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to ensure adequate exposure can be obtained prior to
randomization.
Surgical resection will be carried out with at least 1
cm margins. At the time of surgery circumferential
margins will be taken and sent for frozen section.
The resection will be revised until negative margins
are obtained if feasible. Wounds may be closed by
primary closure, local flaps (i.e. buccal or palatal
flaps) or allowed to heal by secondary intention at
the discretion of the treating surgeons. Free flap and
regional flaps are not allowed.
Standard selective neck dissections for the lymph node
areas at risk will be performed at the time of transoral
resection, or as a staged procedure 2 weeks prior to the
primary site resection. At this time the lingual and facial
branches of the ipsilateral external carotid artery must
be ligated on the side ipsilateral to the primary tumor.
Patients with tonsillar, lateral palate and lateral
pharyngeal cancers, with < 1 cm of base of tongue or palate extension, will undergo ipsilateral neck dissections
only. All other patients will undergo bilateral neck dissections. Selective neck dissections will be limited to
levels 2–4, unless levels 1 or 5 are involved.
If there is a positive margin at the time of TOS at the
primary site, an attempt to clear the positive margin
transorally will be allowed. If a positive or close margin
is found on the final pathology from the transoral resection, an attempt to clear the margin transorally is
allowed within 4 weeks of the original TOS resection.
This can be done with or without the robot at the surgeon’s discretion.
A tracheostomy is strongly recommended, but not
mandatory, to provide airway protection in the event of
swelling and/or bleeding.

Adjuvant radiotherapy Adjuvant radiotherapy will be
determined based on pathological findings. No more
than 6 weeks should elapse between the date of surgery
and the initiation of adjuvant therapy.
Adjuvant radiotherapy is required for the following
risk factors:
 ENE
 Positive margins or close resection margins (< 3

mm)
 More than 1 lymph node positive, or any lymph

node > 3 cm in size on pathology
Primary TOS (Arm 2)

Patients with easily accessible oropharyngeal tumors (determined by the consulting surgeon), will proceed directly to TOS. If adequate transoral access is in question,
patients will undergo an examination under anesthesia

 LVI
 pT3–4 disease

In situations where PNI alone is present, without the
other risk factors above, adjuvant RT is at the discretion
of the treating physicians.
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Patients with positive margins or ENE will receive a 6week course of radiation as follows:
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Table 3 Specific RT volume definition volumes for Arm 2
(Primary TOS) if adjuvant RT is required
Radiotherapy Volume

 60 Gy in 30 fractions: Area of positive margins or

ENE
 54 Gy in 30 fractions: Operative bed, including
primary tumor location and all dissected nodal levels
 48 Gy in 30 fractions: Undissected areas considered
to be at low-risk of harbouring microscopic disease.
Patients without positive margins or ENE will receive
a 5-week course of radiation as follows:

With ENE or positive
margins (30
fractions over 6
weeks)

Definition
Without ENE or
positive margins (25
fractions over 5
weeks)

CTV60

Areas of positive margins
and/or ENE

CTV54

CTV50

Entire tumor bed and any
dissected neck nodal
levels

CTV48

CTV45

Undissected nodal areas
that must be treated
based on pathological
results.
Treatment volumes must
include nodal levels
adjacent to areas
containing involved
nodes (eg. if there is a
level II node positive,
levels Ib and V must be
included)
– All patients with N1
(ipsilateral) nodal
disease:
Ipsilateral: Ib, II-V,
RP
Contralaterala: II-IV,
RP only if extension
to posterior
pharyngeal wall or
soft palate
– All patients with N2
disease:
Ipsilateral and
contralateral: Ib, II-V,
RP

 50 Gy in 25 fractions: Operative bed, including

primary tumor location and all dissected nodal levels
 45 Gy in 25 fractions: Undissected areas considered

to be at low-risk of harbouring microscopic disease.
Concurrent chemoradiation will not be delivered in
the adjuvant setting unless gross tumor is left behind at
the primary site or in the neck AND the patient would
have received chemotherapy had they been randomized
to Arm 1. Chemotherapy is NOT used for patients with
ENE or positive margins. Retrospective surgical data do
not support an OS benefit to the use of chemotherapy in
HPV+ patients with ENE [19].
Specific radiotherapy volume definitions for Arm 2 are
described in Table 3. In all cases a 5 mm CTV to PTV
expansion is to be used.
The AJCC 8th edition has a pathologically based
staging system for HPV+ patients treated with primary surgery that differs significantly from the clinically based staging system used for patients treated
with primary radiation. All surgically treated patients
will be separately re-staged after the final pathology is
available.
In the unlikely event of residual gross disease, the patient should then receive adjuvant treatment using the
dose fractionations in Arm 1. In the unlikely scenario
where a patient is deemed to have highly aggressive disease (e.g. frank growth/progression during the postsurgical interval), the radiation oncologist may elect to
treat with a standard (non-de-escalated) dose of 70 Gy in
35 fractions. Treatment breaks, early RT termination
and discontinuation of systemic therapy is at the discretion of the treating oncologist based on patient treatment toxicity.

a

If treating the contralateral neck

 no posterior pharyngeal wall extension
 no ENE
 N0, or only a single ipsilateral lymph node positive

Unilateral radiation is optional if the following criteria
are ALL met






tonsil primary
< 1 cm extension into the tongue base or palate
no posterior pharyngeal wall extension
no ENE
more than one ipsilateral lymph node positive, but
are all less than 6 cm, and are all in level II.

Unilateral vs. Bilateral radiation

Unilateral radiation is recommended if the following criteria are ALL met:
 tonsil primary
 < 1 cm extension into the tongue base or palate

In all other cases, bilateral radiation is mandatory.
These criteria apply to all patients in Arm 1, and to
patients in Arm 2 who require adjuvant RT. For the
patients in Arm 2 who receive adjuvant RT, these criteria are based on the pathological findings and
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intraoperative findings, not the pre-operative clinical
findings.
Radiotherapy technique, immobilization, localization and
planning

Intensity modulated radiotherapy (IMRT) will be used
for all patients in this study. IMRT can be delivered
using static-beam techniques or rotational techniques
(e.g. Tomotherapy or Volumetric Modulated Arc Therapy [VMAT]). A custom thermoplastic shell will be used
to immobilize all patients. Patients will then undergo a
planning CT simulation (head and neck to below the
clavicles, slice thickness 3 mm or less.) Patients in Arm 1
will receive contrast (unless contraindicated). For patients in both arms, when necessary, the planning CT
will be fused with other diagnostic imaging).
Organ at risk (OAR) contouring definitions, dose constraints and planning priorities are shown in Additional file 1, adapted from RTOG protocols 1016 [20]
(Arm 1) and 0920 [21] (Arm 2), HN-002 [15], ECOG3311 [16] and the NCIC-CTG HN6 protocol [22]. Dose
constraints are the same whether 25 or 30 fractions are
delivered, as the radiobiological conversion factor is
small.
Plans will be normalized to ensure that 95% of each
PTV is covered by 100% of the prescription dose for that
volume. 99% of each PTV must receive at least 93% of
the prescription dose. The maximum dose must be less
than 115% of the highest prescription dose.
Quality assurance
Radiotherapy quality assurance

A quality assurance protocol is used to ensure safe and
efficacious treatment with the following elements
present for each patient:
 Discussion of each radiotherapy plan at head and

neck quality assurance (QA) rounds prior to, or
within the first week of treatment
 Physics staff will confirm all dose delivery for IMRT
plans (including arc-based treatments) before
treatment.
 Cone-beam CT and/or orthogonal x-rays will be
used daily to verify treatment positioning, as per institutional standard practice.
 Prior to enrolling patients, each centre will be given
a sample CT dataset for contouring, planning and
physics QA. Enrollment can begin once the plan and
QA have been approved at the London Regional
Cancer Program (LRCP).
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to be short for early-stage cases, with significant improvements in operative time after 20 cases (but not oncologic outcomes) as learning occurs [23]. Surgeons will
be required to complete a “Surgical Credentialing Questionnaire” based closely on the ECOG-3311 credentialing criteria (Additional file 2). This includes 1) being
fellowship trained in head and neck surgical oncology, 2)
having carried out at least 20 transoral oropharyngeal
cancer resections as primary surgeon, 3) providing operative notes for 10 of those cases, 4) a minimum of 5
oropharyngeal resections in the last year and 5) perform
at least 30 neck dissections per year.
Individual surgeons will be reviewed for surgical quality after every 5 surgical cases by the principal investigator (AN). Bleeding or positive margin rates of greater
than 20% may result in exclusion from the trial at the
discretion of the principal investigators. The occurrence
of an oropharyngeal bleeding fatality or severe anoxic
brain injury in the absence of a tracheostomy may also
result in the exclusion of the centre from the trial.
Centres will be reviewed for surgical quality after 5, 10
and 15 surgical cases by the principal investigators.
Bleeding or positive margin rates of greater than 20%
may result in exclusion from the trial at the discretion of
the principal investigators. The occurrence of an oropharyngeal bleeding fatality or severe anoxic brain injury in
the absence of a tracheostomy may also result in the exclusion of the centre from the trial.
Pathology reporting of ENE: The electronic case report
forms must include a description of ENE using the same
descripTOS as the ECOG-3311 trial:
 absent (node without metastasis or nodal metastasis

with smooth/rounded leading edge confined to
thickened capsule/pseudocapsule)
 minimal (tumor extends ≤1 mm beyond the lymph
node capsule)
 present - extensive (tumor extends > 1 mm beyond
the lymph node capsule (includes soft tissue
metastasis))
Subject discontinuation / withdrawal

Subjects may voluntarily discontinue participation in the
study at any time. If a subject is removed from the study,
the clinical and laboratory evaluations that would have
been performed at the end of the study should be obtained. If a subject is removed because of an adverse
event, they should remain under medical observation as
long as deemed appropriate by the treating physician.
Follow-up evaluation

Surgery quality assurance

The learning curve for surgeons carrying out transoral
oropharyngeal cancer resections has been demonstrated

Day 1 of follow-up will be the first day of radiotherapy
(Arm 1) or the date of surgery (Arm 2); however, survival will be calculated from the date of randomization.
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The follow-up schedule is summarized in Additional file 3, and is the same as the follow-up schedule
of ORATOR [24]. On Arm 1 patients will be seen during
treatment, for a post-treatment clinical assessment at 4–
6 weeks. Post-treatment imaging with a CT or PET/CT
of the neck will be obtained. On Arm 2 a post-operative
assessment will occur at 2 weeks with adjuvant radiotherapy beginning within 6 weeks of surgery if required.
If radiotherapy is delivered the same treatment and
post-treatment assessments will occur as on Arm 1, A
return visit with the surgeon will occur at 3 months from
the date of surgery. On both arms patients will be seen
every 3 months up to 2 years and then every 6 months
thereafter (up to 5 years) from the start of treatment,
with clinical, toxicity and QOL assessments (Additional
file 3). For patients in both arms, a CT of the neck, and
chest, MRI of the neck with CT of the chest or whole
body PET/CT will be obtained at 12 months. Additional
imaging or laboratory investigations and additional treatment (eg. Salvage treatment) will be carried out at the
discretion of the treating physicians.
Disease progression and new primary

In the event of disease progression, the details of new or
recurrent disease and treatment details will be captured
in the case report form. Audiologic assessments, bloodwork and QOL questionnaires should continue to be
completed according to the follow up schedule (Additional file 3). All ongoing adverse events (AEs) at the
time of progression should be followed until resolution.
Subsequent imaging after progression can be completed
at the discretion of the treating investigator.
Salvage surgery after primary radiotherapy Treatment
of residual disease at the site of the primary tumor will
be determined by the treating physicians, and should include surgical salvage if feasible.
Management of residual enlarged lymph nodes in the
neck should be guided by standard institutional practice.
In general, for patients with residual enlarged nodes on
CT, a PET-CT is preferred to confirm FDG avidity prior
to neck dissection. If the PET-CT is negative in the setting of enlarged nodes on CT, then close interval followup with repeat CT every 2–3 months is recommended
until the lymph nodes resolve. If PET-CT is unavailable,
any nodes > 1 cm in short axis should, at a minimum, be
carefully followed with repeat CT every 2–3 months
until the lymph nodes resolve, with neck dissection at
the discretion of the treating physician.
Salvage surgery for the primary tumor or lymph nodes
within 5 months of treatment will be considered part of
the initial treatment package and scored as persistent
disease, not as recurrence. Surgery beyond 5 months
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post-treatment will be scored as recurrence if malignancy is evident in the pathology specimen.
Measurement of outcomes
 Survival outcomes:

OS: time from randomization until death from
any cause
PFS: time from randomization to either
progression or death, whichever occurs first.
 QOL outcomes (measured at baseline and at 6month intervals except PNQ):
MDADI
EORTC QLQ-C30 and H&N35 scales
NDII
VHI-10
PNQ will be completed at 1 year posttreatment.
 Economic assessment:
EQ-5D-5 L: administered at baseline and 6
month intervals. Quality adjusted life years
(QALYs) will be assessed as the area under the
preference-weighted survival curve. Overall costs
of each treatment strategy will be abstracted from
the available literature. The incremental cost effectiveness ratios (ICERs) between treatment arms
will be compared through the standard method of
ratio between differences in costs and QALYs.
Point estimates for these differences can be derived from multivariable generalized estimating
equations (GEE) or general linear model (GLM)
analyses.
 Toxicity outcomes:
CTC-AE toxicities will be recorded during
treatment and at every follow-up visit.
Statistical considerations
Randomization

Patients will be randomized between Arm 1: Arm 2
stratified based on smoking status (< 10 pack-years vs.
≥10 years) in a 1:1 ratio in a permutated block design.
The randomization sequence is known only to the statistician and uploaded into a restricted-access database
(REDCap) housed on secure hospital servers at LHSC
[25]. Upon enrollment of a patient, the database will be
accessed by the trial coordinator to obtain the next
intervention in the random sequence, for the pertinent
stratum, which will then be assigned to the patient.
Sample size calculation

The 2-year OS in each arm, based on the results of
ORATOR, is estimated to be 94%. A 2-year OS of < 85%
will be considered inadequate. In order to differentiate
an OS of 94% vs. 84% using a 1-sided one-sample
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binomial test, with 80% power and alpha of 0.05, with
10% dropout, 70 patients are needed in each arm (140
total).
Analysis plan

Patients will be analyzed in the groups to which they are
assigned (intention-to-treat). Comparisons of OS and
PFS with historical controls will be evaluated using a
one-sided binomial test. The 2-year PFS in this cohort is
estimated to be approximately 85%, based on the results
of CCTG HN6 [22]. If the 2-year PFS is < 75%, it will be
considered unacceptable. Therefore, PFS in each arm
will be compared against a benchmark PFS of 74%. A
comparison of OS and PFS between the two treatment
arms will also be conducted, using the stratified log-rank
test (stratified by smoking pack-year history). With a
sample size of 140 patients, we will have 80% power to
detect a 10% superiority in OS in either arm (assuming
baseline OS of 94% in whichever arm is superior), using
a two-sided alpha of 0.05. A two-sample T-test will be
used to compare QOL scores at 1-year (excluding PNQ).
The percentage of patients in each arm who experience
a clinically significant QOL decline (10 points) will also
be reported. Pre-planned subgroup analysis will occur
based on the stratification variable (smoking pack-year
history). A Cox proportional hazards multivariable regression analysis will be used to determine baseline factors predictive of survival. QOL analysis for secondary
endpoints will be performed in the same way as the
ORATOR trial using linear mixed-effects models [24].
The original ORATOR trial will be used for additional
historical controls [12]. A comparison will occur between HPV+ patients in ORATOR (who were treated
with more aggressive approaches) and ORATOR2 to assess differences in QOL and time-to-event outcomes.
Data safety monitoring committee

The data safety monitoring committee (DSMC), consisting of at least one surgical oncologist, one radiation oncologist, and one medical oncologist not involved in the
study and without competing interests, will meet biannually after study initiation to review toxicity outcomes. The DSMC can recommend modification of the
trial based on toxicity outcomes.
After half of the patients are enrolled and followed for
6 months, one interim analysis will take place. For this
interim analysis, OS at 2-years will be calculated for each
arm. The DSMC may recommend cessation or modification of the trial if any of these two criteria are met:
1. The rate of grade 5 toxicity definitely related to
treatment is > 5% in either arm
2. The upper bound of the 95% confidence interval of
OS at 2 years does not include 94%.
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Biomarker studies

All of the biomarker studies described in this section
will be performed in Dr. Anthony Nichols’ laboratory
located at the London Regional Cancer Program, in
London, Ontario. All specimens will be labeled solely
with the patient’s unique study identifier number,
stored in a secure facility at London Health Sciences
Centre (LHSC), and will be accessed only by clinical
trial staff. Details are provided in Additional file 4.
Ten mL of blood shall be drawn pre-operatively into
a heparinized (green top) tube and directly transported to Dr. Nichols’ lab. At the end of the study
pre-treatment formalin fixed paraffin embedded
(FFPE) primary site biopsy specimens will be retrieved
in 10 slides 8 μm thick as well as three 1 mm core
punch biopsies from the FFPE blocks and transported
to Dr. Nichols’ lab. For patients treated at the lead
centre (LRCP) and randomized to primary surgery a
fresh frozen specimen will be collected. Specifically, at
the time of operation the main specimen will be
taken to pathology frozen section room and a portion
from the center of the specimen will be taken with
the assistance of the pathologist and frozen at − 80
degrees Celsius. This will be transported to Dr.
Nichols’ lab.
Human papillomavirus testing P16 testing (which is an
excellent surrogate marker of HPV status) is required
for enrollment. This will be done through the routine
pathology laboratories as per current routine clinical
care. The accompanying biomarker study will determine
HPV status by real-time PCR, not for the purposes of
randomization, but to confirm the accuracy of p16 results and also for subtyping of HPV strain. Pretreatment FFPE primary site biopsy specimens will be
retrieved in 10 slides 8 μm thick from the FFPE blocks.
DNA will be extracted from the specimens for HPV testing by real-time PCR.
Whole genome sequencing analysis DNA will be extracted either from fresh tumor or from formalin fixed
specimens for patients undergoing TOS, as well as 10
mL of venous blood drawn prior to the initiation of
treatment. Specimens yielding DNA of adequate quantity and quality (> 5 μg, OD between 1.8 and 2.0) will be
subjected to high-throughput sequencing and gene copy
number.

Ethical considerations
The Principal Investigator will obtain ethical approval
and clinical trial authorization by competent authorities
according to local laws and regulations.
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Institutional Review Board (IRB) / Research Ethics Board
(REB)

The protocol (and any amendments), the informed consent form, and any other written information to be given
to subjects will be reviewed and approved by a properly
constituted Institutional Review Board (IRB)/Research
Ethics Board (REB), operating in accordance with the
current federal regulations (e.g., Canadian Food and
Drug Regulations (C.05.001); US Code of Federal Regulations (21CFR part 56)), ICH GCP and local regulatory
requirements. A letter to the investigator documenting
the date of the approval of the protocol and informed
consent form will be obtained from the IRB/REB prior
to initiating the study. Any institution opening this study
will obtain REB IRB/REB approval prior to local
initiation.
Informed consent

The written informed consent form is to be provided to
potential study subjects (Additional file 5) should be approved by the IRB/REB and adhere to ICH GCP and the
ethical principles that have their origin in the Declaration of Helsinki. The investigator is responsible for
obtaining written informed consent from each subject,
or if the subject is unable to provide informed consent,
the subject’s legally acceptable representative, prior to
beginning any study procedures and treatment(s). The
investigator should inform the subject, or the subject’s
legally acceptable representative, of all aspects of the
study, including the potential risks and benefits involved.
The subject will be given ample time and opportunity to
ask questions prior to deciding about participating in the
study and be informed that participation in the study is
voluntary and that they are completely free to refuse to
enter the study or to withdraw from it at any time, for
any reason.
The informed consent will be signed and dated by the
subject, or the subject’s legally acceptable representative,
and by the person who conducted the informed consent
discussion. A copy of the signed and dated written informed consent form will be given to the subject or the
subject’s legally acceptable representative. The process
of obtaining informed consent will be documented in
the patient source documents.
Confidentiality

The names and personal information of study participants will be held in strict confidence. All study records
(CRFs, safety reports, correspondence, etc.) will only
identify the subject by initials and the assigned study
identification number. The data coordinator will maintain a confidential subject identification list (Master List)
during the course of the study. Access to confidential information (i.e., source documents and patient records) is
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only permitted for direct subject management and for
those involved in monitoring the conduct of the study
(i.e., Sponsors, CRO’s, representatives of the IRB/REB,
and regulatory agencies). The subject’s name will not be
used in any public report of the study.
Data storage

All data will be stored on REDCap [25] a secure web application for building and managing online databases
commonly used in the clinical trials research community. Ongoing auditing will be performed by the LRCP
clinical trials unit, independent from the trial investigators and sponsor. All of the biomarker studies described
in this section will be performed in Dr. Anthony
Nichols’ laboratory located at the LRCP, in London, Ontario. All specimens will be labeled solely with the patient’s unique study identifier number, stored in a secure
facility at LHSC, and will be accessed only by clinical
trial staff.
Adverse events

The severity of adverse events will be evaluated using
the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 grading scale [26]. Any grade 4 or
5 adverse event that is definitely, probably, or possibly
the result of protocol treatment must be reported to the
Principal Investigator and Central Office within 24 h of
discovery. The Serious Adverse Event (SAE) report form
is to be completed with all available information and
uploaded to the REDCap SAE page. The Central Office
must be notified by email or telephone that a new SAE
form has been uploaded into REDCap. It is the responsibility of each local Principal Investigator to report all
SAEs to their REB as per local REB requirements. The
Principal Investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the
regulatory authority (ies).

Data sharing statement
De-identified participant data from this trial will not be
shared publicly, however, the full protocol will be published along with the primary analysis of the outcomes.
Protocol ammendments and trial publication
Trial registration elements are summarized in Additional file 6. Any modifications to the trial protocol
must be approved and enacted by the principal investigator (Current version: 1.3 on March 15, 2019). Protocol
amendments will communicated to all participating centres, investigators, IRBs, and trial registries by the principal investigator. Any communication or publication of
trial results will be led by the principal investigator, and
is expected to occur within 1 year of the primary
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analysis. Trial results will remain embargoed until conference presentation of an abstract or until information
release is authorized. Authorship of the trial abstract
and ultimately the full manuscript will be decided by the
principal investigator at the time of submission. Professional writers will not be used for either abstract or
manuscript preparation.

Discussion
Patients with HPV+ OPC have substantially better treatment response and OS than HPV- disease [3]. This has
spurred increasing interest in de-escalation of therapy
with the hopes of reducing treatment-related toxicity.
ORATOR2 is a multi-center phase II trial that aims to
randomize 140 patients to two de-escalated interventions: de-escalated radiotherapy (± chemotherapy) or
TOS (± adjuvant radiotherapy). The primary radiotherapy arm is based on the chemoradiation arm of HN002
[15] and the TOS arm is partially based on the treatment
paradigm of ECOG-3311 [16].
This trial will assess the safety of both of these deescalation approaches, comparing each to historical controls, and will allow for comparisons of OS, PFS and
QOL between the two interventions. There is a paucity
of data comparing primary RT and primary surgical approaches to oropharyngeal cancers. To date, the only
randomized study examining this question is ORATOR,
which enrolled patients regardless of HPV status, and included a small number of patients. ORATOR2 will allow
for an assessment of both approaches in the early Tstage HPV+ patient population. Furthermore, the ORATOR trial can be used for additional historical controls,
with a planned comparison between HPV+ patients in
ORATOR (who were treated with more aggressive approaches) and ORATOR2 to assess differences in QOL
and time-to-event outcomes.
A recruitment video has been created to help patients
and the public understand the rationale and design behind the trial, and to help reach the target accrual (www.
orator2.com).
Results of ORATOR2 are expected to provide data
that will help guide treatment decisions in the management of HPV-associated OPC, which remains one of the
most contentious issues in head and neck oncology.
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Additional file 5. Study Information and Informed Consent Form.
Additional file 6. World Health Organization Trial Registration Dataset.
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